 Proactive Investors Australia | REVA Medical: patient enrolment underway in Europe for pilot trial of coronary ... Proactive Investors Australia REVA Medical (ASX: RVA) has begun enrolling patients in Europe in a pilot study of its ReZolve™ sirolimus-eluting bioresorbable coronary scaffold to treat blockages caused by coronary artery disease. The RESTORE trial is evaluating the safety and ... |
